行情

AERI

AERI

Aerie Pharma
NASDAQ

实时行情|Nasdaq Last Sale

13.97
-0.49
-3.39%
盘后: 13.97 0 0.00% 16:00 07/02 EDT
开盘
14.75
昨收
14.46
最高
14.97
最低
13.81
成交量
80.37万
成交额
--
52周最高
26.68
52周最低
10.80
市值
6.49亿
市盈率(TTM)
-3.1702
分时
5日
1月
3月
1年
5年

分析师评级

14位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测AERI价格均价为32.33,最高价位50.00,最低价为16.00。

EPS

AERI 新闻

更多
Is Aerie Pharmaceuticals a Buy?
Wall Street has given the eye-care specialist the cold shoulder in 2020. Is that an opportunity for individual investors?
Motley Fool · 3天前
Aerie Pharmaceuticals Inc (AERI): Hedge Funds Are Nibbling
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter
Insider Monkey · 06/15 22:04
Aerie Pharmaceuticals Appoints Peter J. McDonnell, M.D., to the Companys Board of Directors
Business Wire · 06/11 11:30
Aerie Looks Modestly Undervalued Despite High Cash Burn
Seeking Alpha - Article · 06/06 13:33
Aerie (AERI) Up 1.9% Since Last Earnings Report: Can It Continue?
Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 06/05 15:31
Edited Transcript of AERI earnings conference call or presentation 6-May-20 9:00pm GMT
Thomson Reuters StreetEvents · 06/03 08:40
Oppenheimer Maintains Outperform on Aerie Pharmaceuticals, Raises Price Target to $24
Oppenheimer maintains Aerie Pharmaceuticals (NASDAQ:AERI) with a Outperform and raises the price target from $22 to $24.
Benzinga · 06/01 15:38
Was The Smart Money Right About Aerie Pharmaceuticals Inc (AERI)?
Hedge funds don't get the respect they used to get. Nowadays investors prefer passive funds over actively managed funds. One thing they don't realize is that 100% of the passive funds didn't see the coronavirus recession coming, but a lot of hedge funds did. E
Insider Monkey · 05/11 23:15

所属板块

生物技术和医学研究
+0.68%
制药与医学研究
+0.61%

热门股票

代码
价格
涨跌幅

AERI 简况

Aerie Pharmaceuticals, Inc.是一家临床阶段制药公司。该公司致力于发现、开发和商业化治疗青光眼和其他眼部疾病的治疗方法。该公司的主要候选药物是Rhopressa和Roclatan。其候选药物旨在降低患有开角型青光眼和高眼压症患者的眼内压(IOP)。Rhopressa是一种每日1次的滴眼液和三重功效的奈他地尔滴眼液。Rhopressa的活性成分通过抑制Rho激酶(ROCK)和去甲肾上腺素转运蛋白(NET)起作用。Roclatan是一种每日1次的四重功效候选药物,是Rhopressa和拉坦前列素的固定剂量复合剂。拉坦前列素是用于治疗青光眼的处方药。Rhopressa和Roclatan正处于III期临床试验阶段。
展开

微牛提供Aerie Pharmaceuticals Inc(NASDAQ-AERI)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的AERI股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易AERI股票基本功能。